Post stroke fatigue afflicts as many as 70% of the 400,000 Canadians with stroke. There are no treatments for post stroke fatigue supported by research studies, however, exercise and the medication Modafinil have shown promise in alleviating symptoms in small studies. For this study we are looking at combining Modafinil with an instructor-led, home-based exercise program based on the “Fitness and Mobility Exercise (FAME)” program to help improve fatigue symptoms after stroke. A home-based exercise program delivered by videoconference allows participants to join exercise sessions over video from their homes, without having to travel to a different location. The purpose of this study is to: - Test whether Modafinil and exercise can improve the symptoms of post-stroke fatigue - Investigate the effects of Modafinil and exercise on other areas including but not limited to quality of life, fitness, mood, and health care utilization.

This study explores how your community placement during pre-clerkship has influenced your experience in clerkship. During your first two years of medical school, you completed a year-long placement with a community organization as part of the Community Engaged Learning program. Now that you are in clerkship and working in clinical settings like hospitals, we want to understand whether and how those community experiences have shaped the way you interact with patients, make clinical decisions, and think about your role as a future doctor. We are interested in hearing about what you remember most from your community placement, whether you've found yourself applying any lessons from that experience during your clinical rotations, and what aspects of the program were most meaningful or could be improved. Your insights will help us understand the lasting impact of community-based learning and will inform improvements to the program for future medical students. If you choose to participate, you will join a one-on-one interview with a member of our research team via Zoom. The interview will take about 45-60 minutes, and you'll receive the questions in advance so you can think about your experiences. We'll ask you to share examples of how your community placement has or hasn't influenced your work in clerkship, what elements of the program stood out to you, and what suggestions you have for making it better. Your participation is completely voluntary, and your honest feedback, whether it be positive or critical, is valuable and will not affect your standing in the medical program in any way. You will receive a $10 giftcard as compensation for your time.

Pelvic organ prolapse is a common condition, and many women require surgery to treat bothersome symptoms. Good preoperative education is essential so patients understand the surgery, know what to expect, and feel prepared for recovery. However, current counselling methods often do not fully meet patients’ needs. This study aims to develop a patient-centred education toolkit for women undergoing prolapse surgery. Women with lived experience of prolapse surgery will partner with researchers to co-create written, online, and interactive educational resources. The goal is to improve patients’ understanding, preparedness, satisfaction, and overall surgical experience.

The purpose of this study is to try and understand how the adolescent brain responds to pain. The first part of the study involves teens filling out an online questionnaire, which asks about pain, sleep and mental health. They will receive a $10 gift card for answering this questionnaire. One week later, we will have the teen come to the Alberta Children's Hospital. Using a device that applies thermal heat, we will establish their threshold for low, medium and high heat on their forearm. We will then apply 3 creams to their forearm: 1) one will enhance sensitivity to pain; 2) one will have no effect on pain; and 3) one will decrease sensitivity to pain. We will test their responses to the creams both outside and inside the MRI. Transportation to and parking at the hospital will be reimbursed via gift card. Teens will receive an additional $20 gift card and pictures of their brain to thank them for participating in this study.

This study looks at how migraines affect the brain at different ages. We will compare brain imaging of people with chronic migraine (at least 15 headache attack days/month) to those without and we want to compare children/youth and adults. This will help us find differences and similarities between adults and youth with migraine with the expectation that better understanding migraine will lead to better treatments in future. This study will have four groups: 1) children/youth (age 8-18y) with chronic migraine, 2) children/youth (age 8-18 y) without migraine, 3) adults (age 30-50y) with chronic migraine, and 4) adults (age 30-50y) without migraine.

Many adults experience problems related to alcohol, cannabis, or opioids, and they often face barriers to finding timely, stigma-free support. Complex mental health systems, long wait times, and fear of judgment can make it difficult for adults to access care. This study will evaluate a new artificial intelligence-based tool called JARA (Judgment-free, Assessment, and Resource Assistant). JARA is a conversational agent designed to help people aged 18+ identify their needs, assess risk levels, and find appropriate services. The goal of this study is to understand whether JARA is acceptable, usable, and helpful from the perspectives of adults, caregivers, and clinicians, and to inform further development of the tool.

This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with NASH or MASH improve their liver function. Participants are put into 2 groups randomly, which means by chance. 1 group gets survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Each participant has twice the chance of getting survodutide. Participants and doctors do not know who is in which group. Participants inject survodutide or placebo under their skin once a week. All participants regularly receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for up to 4 and a half years. During this time, they visit the study site or have a remote visit by video call every 2, 4 or 6 weeks for about a 1 year and 5 months. After this time participants visit the trial site or have a remote visit every 3 months until the end of the study. The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. At some visits the liver parameters are measured using different imaging methods. The participants also fill in questionnaires about their symptoms. The results are compared between the groups to see whether the treatment works.

This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory). Langerhans cell histiocytosis is a type of disease that occurs when the body makes too many immature Langerhans cells (a type of white blood cell). When these cells build up, they can form tumors in certain tissues and organs including bones, skin, lungs and pituitary gland and can damage them. This tumor is more common in children and young adults. DAY101 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Using DAY101 may be effective in treating patients with relapsed or refractory Langerhans cell histiocytosis.

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine, and procarbazine hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Adding immunotherapy to the standard treatment of chemotherapy with or without radiation may increase survival and/or fewer short-term or long-term side effects in patients with classical Hodgkin lymphoma compared to the standard treatment alone.

This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Researchers want to find out what effects, good and/or bad, adding nivolumab to chemotherapy has on patients with newly diagnosed NPC. In addition, they want to find out if children with NPC may be treated with less radiation therapy and whether this decreases the side effects of therapy.